Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avadomide - Celgene Corporation

Next Previous
Drug Profile

Avadomide - Celgene Corporation

Alternative Names: CC 122

Latest Information Update: 08 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Bristol-Myers Squibb; Celgene Corporation; H. Lee Moffitt Cancer Center and Research Institute; Juno Therapeutics
  • Class Antineoplastics; Piperidones; Quinazolines
  • Mechanism of Action CRBN protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Liver cancer; Non-Hodgkin's lymphoma
  • Phase I Solid tumours
  • No development reported Glioblastoma; Multiple myeloma

Most Recent Events

  • 08 Oct 2024 Celgene terminates a phase I trial in Solid tumours (Late-stage disease) in Japan das it is replaced with another clinical trial (NCT02509039)
  • 06 May 2024 Celgene terminates a phase I trial in Non-Hodgkin lymphoma (Late-stage disease) in Japan das it is replaced with another clinical trial (NCT02509039)
  • 12 Dec 2023 Celgene terminates a phase I trial in Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada, Italy, USA and France (PO) as the trial was replaced with another clinical trial (NCT02031419)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top